-
公开(公告)号：US20190269683A1
公开(公告)日：2019-09-05
申请号：US16258024
申请日：2019-01-25
发明人： Mark Thomas Miller , Corey Anderson , Vijayalaksmi Arumugam , Brian Richard Bear , Haley Marie Binch , Jeremy J. Clemens , Thomas Cleveland , Erica Conroy , Timothy Richard Coon , Bryan A. Frieman , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Sara Sabina Hadida-Ruah , Haripada Khatuya , Pramod Virupax Joshi , Paul John Krenitsky , Chun-Chieh Lin , Gulin Erdogan Marelius , Vito Melillo , Jason McCartney , Georgia McGaughey Nicholls , Fabrice Jean Denis Pierre , Alina Silina , Andreas P. Termin , Johnny Uy , Jinglan Zhou
IPC分类号： A61K31/506 , A61K31/4525 , C07D403/12 , A61K31/4709 , A61K31/4545 , C07D405/14 , C07D417/12 , A61K31/497 , C07D231/12 , C07D401/14 , A61K31/4439 , C07D401/12 , A61K31/404 , C07D209/42 , A61K31/415 , C07D231/14 , C07D213/84 , A61K31/44 , A61K31/444 , A61K31/4418 , C07D213/82 , A61J1/03 , C07D213/64 , C07D209/49 , C07D209/18 , C07D407/12 , C07D239/34 , C07D403/10 , C07D235/24 , C07D401/04 , C07D231/20 , C07D213/73 , C07D413/14 , A61K31/496
摘要： The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
公开(公告)号：US20210052584A1
公开(公告)日：2021-02-25
申请号：US16836155
申请日：2020-03-31
发明人： Mark Thomas Miller , Corey Anderson , Vijayalaksmi Arumugam , Brian Richard Bear , Hayley Marie Binch , Jeremy J. Clemens , Thomas Cleveland , Erica Conroy , Timothy Richard Coon , Bryan A. Frieman , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Sara Sabina Hadida-Ruah , Haripada Khatuya , Pramod Virupax Joshi , Paul John Krenitsky , Chun-Chieh Lin , Gulin Erdogan Marelius , Vito Melillo , Jason McCartney , Georgia McGaughey Nicholls , Fabrice Jean Denis Pierre , Alina Silina , Andreas P. Termin , Johnny Uy , Jinglan Zhou
IPC分类号： A61K31/506 , C07D213/82 , A61K31/4418 , A61K31/444 , A61K31/44 , C07D213/84 , C07D231/14 , A61K31/415 , C07D209/42 , A61K31/404 , C07D401/12 , A61K31/4439 , C07D401/14 , C07D231/12 , A61K31/497 , C07D417/12 , C07D405/14 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/4525 , A61J1/03 , C07D403/12 , C07D413/14 , C07D213/73 , C07D231/20 , C07D401/04 , C07D235/24 , C07D403/10 , C07D239/34 , C07D407/12 , C07D209/18 , C07D209/49 , C07D213/64
摘要： The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
公开(公告)号：US20180185364A1
公开(公告)日：2018-07-05
申请号：US15675000
申请日：2017-08-11
发明人： Mark Thomas Miller , Corey Anderson , Vijayalaksmi Arumugam , Brian Richard Bear , Hayley Marie Binch , Jeremy J. Clemens , Thomas Cleveland , Erica Conroy , Timothy Richard Coon , Bryan A. Frieman , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Sara Sabina Hadida-Ruah , Haripada Khatuya , Pramod Virupax Joshi , Paul John Krenitsky , Chun-Chieh Lin , Gulin Erdogan Marelius , Vito Melillo , Jason McCartney , Georgia McGaughey Nicholls , Fabrice Jean Denis Pierre , Alina Silina , Andreas P. Termin , Johnny Uy , Jinglan Zhou
IPC分类号： A61K31/506 , C07D417/12 , C07D405/14 , C07D401/14 , C07D401/12 , C07D231/14 , C07D231/12 , C07D213/84 , C07D213/82 , C07D209/42 , A61K31/497 , A61K31/496 , A61K31/4709 , A61K31/4545 , A61K31/4525 , A61K31/444 , A61K31/4439 , A61K31/4418 , A61K31/44 , A61K31/415 , A61K31/404 , A61J1/03
CPC分类号： A61K31/506 , A61J1/035 , A61K31/404 , A61K31/415 , A61K31/44 , A61K31/4418 , A61K31/4439 , A61K31/444 , A61K31/4525 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/497 , C07D209/18 , C07D209/42 , C07D209/49 , C07D213/64 , C07D213/73 , C07D213/82 , C07D213/84 , C07D231/12 , C07D231/14 , C07D231/20 , C07D235/24 , C07D239/34 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D407/12 , C07D413/14 , C07D417/12
摘要： The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
公开(公告)号：US09782408B2
公开(公告)日：2017-10-10
申请号：US14876525
申请日：2015-10-06
发明人： Mark Thomas Miller , Corey Anderson , Vijayalaksmi Arumugam , Brian Richard Bear , Hayley Marie Binch , Jeremy J. Clemens , Thomas Cleveland , Erica Conroy , Timothy Richard Coon , Bryan A. Frieman , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Sara Sabina Hadida Ruah , Haripada Khatuya , Pramod Virupax Joshi , Paul John Krenitsky , Chun-Chieh Lin , Gulin Erdogan Marelius , Vito Melillo , Jason McCartney , Georgia McGaughey Nicholls , Fabrice Jean Denis Pierre , Alina Silina , Andreas P. Termin , Johnny Uy , Jinglan Zhou
IPC分类号： A61K31/506 , C07D213/82 , A61K31/4418 , A61K31/444 , A61K31/44 , C07D213/84 , C07D231/14 , A61K31/415 , C07D209/42 , A61K31/404 , C07D401/12 , A61K31/4439 , C07D401/14 , C07D231/12 , A61K31/497 , C07D417/12 , C07D405/14 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/4525 , A61J1/03
CPC分类号： A61K31/506 , A61J1/035 , A61K31/404 , A61K31/415 , A61K31/44 , A61K31/4418 , A61K31/4439 , A61K31/444 , A61K31/4525 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/497 , C07D209/18 , C07D209/42 , C07D209/49 , C07D213/64 , C07D213/73 , C07D213/82 , C07D213/84 , C07D231/12 , C07D231/14 , C07D231/20 , C07D235/24 , C07D239/34 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D407/12 , C07D413/14 , C07D417/12
摘要： The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
公开(公告)号：US11426407B2
公开(公告)日：2022-08-30
申请号：US16836155
申请日：2020-03-31
发明人： Mark Thomas Miller , Corey Anderson , Vijayalaksmi Arumugam , Brian Richard Bear , Hayley Marie Binch , Jeremy J. Clemens , Thomas Cleveland , Erica Conroy , Timothy Richard Coon , Bryan A. Frieman , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Sara Sabina Hadida-Ruah , Haripada Khatuya , Pramod Virupax Joshi , Paul John Krenitsky , Chun-Chieh Lin , Gulin Erdogan Marelius , Vito Melillo , Jason McCartney , Georgia McGaughey Nicholls , Fabrice Jean Denis Pierre , Alina Silina , Andreas P. Termin , Johnny Uy , Jinglan Zhou
IPC分类号： C07D213/82 , A61K31/506 , A61K31/4418 , A61K31/444 , A61K31/44 , C07D213/84 , C07D231/14 , A61K31/415 , C07D209/42 , A61K31/404 , C07D401/12 , A61K31/4439 , C07D401/14 , C07D231/12 , A61K31/497 , C07D417/12 , C07D405/14 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/4525 , A61J1/03 , C07D403/12 , C07D413/14 , C07D213/73 , C07D231/20 , C07D401/04 , C07D235/24 , C07D403/10 , C07D239/34 , C07D407/12 , C07D209/18 , C07D209/49 , C07D213/64
摘要： The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
公开(公告)号：US20210047295A1
公开(公告)日：2021-02-18
申请号：US16994875
申请日：2020-08-17
发明人： Alexander Russell Abela , Timothy Alcacio , Corey Anderson , Paul Timothy Angell , Minson Baek , Jeremy J. Clemens , Thomas Cleveland , Lori Ann Ferris , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Anton V. Gulevich , Sara Sabina Hadida Ruah , Clara Kuang-Ju Hsia , Robert M. Hughes , Pramod Virupax Joshi , Ping Kang , Ali Keshavarz-Shokri , Haripada Khatuya , Paul John Krenitsky , Jason McCartney , Mark Thomas Miller , Prasuna Paraselli , Fabrice Jean Denis Pierre , Yi Shi , Muna Shrestha , David Andrew Siesel , Kathy Stavropoulos , Andreas P. Termin , Fredrick F. Van Goor , Johnny Uy , Timothy John Young , Jinglan Zhou
IPC分类号： C07D401/14 , C07D471/14 , A61P11/00 , C07D498/14 , C07D401/04 , C07D231/20
摘要： Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
-
公开(公告)号：US20160095858A1
公开(公告)日：2016-04-07
申请号：US14876525
申请日：2015-10-06
发明人： Mark Thomas Miller , Corey Anderson , Vijayalaksmi Arumugam , Brian Richard Bear , Hayley Marie Binch , Jeremy J. Clemens , Thomas Cleveland , Erica Conroy , Timothy Richard Coon , Bryan A. Frieman , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Sara Sabina Hadida-Ruah , Khatuya Haripada , Pramod Virupax Joshi , Paul John Krenitsky , Chun-Chieh Lin , Gulin Erdgogan Marelius , Vito Melillo , Jason McCartney , Georgia McGaughey Nicholls , Fabrice Jean Denis Pierre , Alina Silina , Andreas P. Termin , Johnny Uy , Jinglan Zhou
IPC分类号： A61K31/506 , A61K31/4418 , A61K31/444 , A61K31/44 , C07D213/84 , C07D231/14 , A61K31/415 , C07D209/42 , A61K31/404 , C07D401/12 , A61K31/4439 , C07D401/14 , C07D231/12 , A61K31/497 , C07D417/12 , C07D405/14 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/4525 , A61J1/03 , C07D213/82
CPC分类号： A61K31/506 , A61J1/035 , A61K31/404 , A61K31/415 , A61K31/44 , A61K31/4418 , A61K31/4439 , A61K31/444 , A61K31/4525 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/497 , C07D209/18 , C07D209/42 , C07D209/49 , C07D213/64 , C07D213/73 , C07D213/82 , C07D213/84 , C07D231/12 , C07D231/14 , C07D231/20 , C07D235/24 , C07D239/34 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D407/12 , C07D413/14 , C07D417/12
摘要： The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
摘要翻译： 本发明的特征在于式I化合物或其药学上可接受的盐，其中R1，R2，R3，W，X，Y，Z，n，o，p和q如本文所定义，用于治疗CFTR介导 疾病如囊性纤维化。 本发明还特征在于药物组合物，治疗方法及其试剂盒。
-
公开(公告)号：US20230233560A1
公开(公告)日：2023-07-27
申请号：US17865220
申请日：2022-07-14
发明人： Mark Thomas Miller , Corey Anderson , Vijayalaksmi Arumugam , Brian Richard Bear , Hayley Marie Binch , Jeremy J. Clemens , Thomas Cleveland , Erica Conroy , Timothy Richard Coon , Bryan A. Frieman , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Sara Sabina Hadida-Ruah , Haripada Khatuya , Pramod Virupax Joshi , Paul John Krenitsky , Chun-Chieh Lin , Gulin Erdogan Marelius , Vito Melillo , Jason McCartney , Georgia McGaughey Nicholls , Fabrice Jean Denis Pierre , Alina Silina , Andreas P. Termin , Johnny Uy , Jinglan Zhou
IPC分类号： A61K31/506 , C07D213/82 , A61K31/4418 , A61K31/444 , A61K31/44 , C07D213/84 , C07D231/14 , A61K31/415 , C07D209/42 , A61K31/404 , C07D401/12 , A61K31/4439 , C07D401/14 , C07D231/12 , A61K31/497 , C07D417/12 , C07D405/14 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/4525 , A61J1/03 , C07D403/12 , C07D413/14 , C07D213/73 , C07D231/20 , C07D401/04 , C07D235/24 , C07D403/10 , C07D239/34 , C07D407/12 , C07D209/18 , C07D209/49 , C07D213/64
CPC分类号： A61K31/506 , C07D213/82 , A61K31/4418 , A61K31/444 , A61K31/44 , C07D213/84 , C07D231/14 , A61K31/415 , C07D209/42 , A61K31/404 , C07D401/12 , A61K31/4439 , C07D401/14 , C07D231/12 , A61K31/497 , C07D417/12 , C07D405/14 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/4525 , A61J1/035 , C07D403/12 , C07D413/14 , C07D213/73 , C07D231/20 , C07D401/04 , C07D235/24 , C07D403/10 , C07D239/34 , C07D407/12 , C07D209/18 , C07D209/49 , C07D213/64
摘要： The present invention features a compound of formula I:
or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.-
公开(公告)号：US11453655B2
公开(公告)日：2022-09-27
申请号：US16994875
申请日：2020-08-17
发明人： Alexander Russell Abela , Timothy Alcacio , Corey Anderson , Paul Timothy Angell , Minson Baek , Jeremy J. Clemens , Thomas Cleveland , Lori Ann Ferris , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Anton V. Gulevich , Sara Sabina Hadida Ruah , Clara Kuang-Ju Hsia , Robert M. Hughes , Pramod Virupax Joshi , Ping Kang , Ali Keshavarz-Shokri , Haripada Khatuya , Paul John Krenitsky , Jason McCartney , Mark Thomas Miller , Prasuna Paraselli , Fabrice Jean Denis Pierre , Yi Shi , Muna Shrestha , David Andrew Siesel , Kathy Stavropoulos , Andreas P. Termin , Fredrick F. Van Goor , Johnny Uy , Timothy John Young , Jinglan Zhou
IPC分类号： C07D401/04 , C07D401/14 , C07D471/14 , A61P11/00 , C07D498/14 , C07D231/20
摘要： Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
-
公开(公告)号：US20180162839A1
公开(公告)日：2018-06-14
申请号：US15836627
申请日：2017-12-08
发明人： Alexander Russell Abela , Timothy Alcacio , Corey Anderson , Paul Timothy Angell , Minson Baek , Jeremy J. Clemens , Thomas Cleveland , Lori Ann Ferris , Peter Diederik Jan Grootenhuis , Raymond Stanley Gross , Anton V. Gulevich , Sara Sabina Hadida Ruah , Clara Kuang-Ju Hsia , Robert M. Hughes , Pramod Virupax Joshi , Ping Kang , Ali Keshavarz-Shokri , Haripada Khatuya , Paul John Krenitsky , Jason McCartney , Mark Thomas Miller , Prasuna Paraselli , Fabrice Jean Denis Pierre , Yi Shi , Muna Shrestha , David Andrew Siesel , Kathy Stavropoulos , Andreas P. Termin , Fredrick F. Van Goor , Johnny Uy , Timothy John Young , Jinglan Zhou
IPC分类号： C07D401/14 , C07D471/14 , C07D498/14 , A61P11/00
摘要： Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.052 秒)
